STOCKS TO BUY: We have identified several stocks that can potentially TRIPLE. Learn more!

Infinity Pharmaceuticals Inc.
INFI : NASDAQ : Health Care

$18.58 -0.88 | -4.52%
Today's Range: 18.35 - 19.70
Avg. Daily Volume: 1,822,600
06/19/13 - 4:00 PM ET

Financial Analysis


INFINITY PHARMACEUTICALS INC's gross profit margin for the fourth quarter of its fiscal year 2012 has significantly increased when compared to the same period a year ago. Sales and net income fell significantly, underperforming compared to the average company in its industry. INFINITY PHARMACEUTICALS INC is extremely liquid. Currently, the Quick Ratio is 17.47 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has increased from the same period last year.

At the same time, stockholders' equity ("net worth") has greatly increased by 1,910.01% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.



Income Statement Q4 FY12 Q4 FY11
Net Sales ($mil)0.022.33
EBITDA ($mil)-46.73-13.15
EBIT ($mil)-47.12-13.61
Net Income ($mil)-46.99-14.06


Balance Sheet Q4 FY12 Q4 FY11
Cash & Equiv. ($mil)326.02115.28
Total Assets ($mil)335.66124.49
Total Debt ($mil)0.037.55
Equity ($mil)310.2115.43


Profitability Q4 FY12 Q4 FY11
Gross Profit Margin0.0-58.88
EBITDA Margin0.0-58.88
Operating Margin0.0-60.97
Sales Turnover0.140.75
Return on Assets-16.07-32.16
Return on Equity-17.39-259.45
Debt Q4 FY12 Q4 FY11
Current Ratio17.674.07
Debt/Capital0.00.71
Interest Expense0.00.54
Interest Coverage0.0-25.11


Share Data Q4 FY12 Q4 FY11
Shares outstanding (mil)47.526.72
Div / share0.00.0
EPS-1.15-0.53
Book value / share6.530.58
Institutional Own % n/a n/a
Avg Daily Volume812910.0732165.0

Valuation


SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. To use another comparison, its price-to-book ratio of 4.87 indicates a significant premium versus the S&P 500 average of 2.40 and a significant discount versus the industry average of 9.29. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, INFINITY PHARMACEUTICALS INC proves to trade at a discount to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
INFI NM Peers 31.28   INFI NM Peers 47.71

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

INFI's P/E is negative making this valuation measure meaningless.

 

Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

INFI's P/CF is negative making the measure meaningless.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
INFI NM Peers 29.97   INFI NA Peers 0.67

Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.

INFI's ratio is negative making this valuation measure meaningless.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
INFI 4.87 Peers 9.29   INFI -3.97 Peers 17.71

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

INFI is trading at a significant discount to its peers.

 

Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

However, INFI is expected to significantly trail its peers on the basis of its earnings growth rate.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
INFI 32.04 Peers 436.93   INFI -49.22 Peers 66.25

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

INFI is trading at a significant discount to its industry on this measurement.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

INFI significantly trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades

Brokerage Partners


Top Rated Stocks Top Rated Funds Top Rated ETFs